Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine a after liver transplant

Transplantation

Volumn 74, Issue 6, 2002, Pages 817-821

  Roberts, Cory A ^a   Stern, David L ^a   Radio, Stanley J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; ARTICLE; AUTOPSY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART HYPERTROPHY; HEART MUSCLE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037183895     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200209270-00015     Document Type: Article

References (26)

1. Kino T, Hatanaka H, Hashimoto M, et al. FK506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249.
2. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256.
3. Todo S, Demetris A, Ueda Y, et al. Canine kidney transplantation with FK506 alone or in combination with cyclosporine and steroids. Transplant Proc 1987; 19(Suppl 6): 57.
4. Collier D, Thiru S, Calne R. Kidney transplantation in the dog receiving FK506. Transplant Proc 1987; 19(Suppl 6): 62.
5. Calne R, Collier D, Thiru S. Observations about FK506 in primates. Transplant Proc 1987; 19(Suppl 6): 63.
6. Todo S, Podesta L, ChapChap P, et al. Orthotopic liver transplantation in dogs receiving FK506. Transplant Proc 1987; 19(Suppl 6): 64.
7. Thiru S, Collier D, Caine R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK506. Transplant Proc 1987; 19(Suppl 6): 98.
8. Ochiai T, Nakajima K, Nagata M et al. Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 191: 1284.
9. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
10. Fung J, Todo S, Jain A, et al. Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications, Transplant Proc 1990; 22(Suppl 1): 6.
11. Todo S, Fung J, Starzl T, et al. Liver, kidney, and thoracic organ transplantation under FK506. Ann Surg 1990; 212: 295.
12. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
13. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423.
14. Japanese FK506 Study Group. Study of FK506 on kidney transplantation: results of an early phase II study. Transplant Proc 1991; 23: 3071.
15. Nomoto S, Fujiwara H, Ban T, et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. Transplant Proc 1994; 26: 855.
16. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894.
17. Dhawan A, Mack D, Langnas A, et al. Immunosuppressive drugs and hypertrophic cardiomyopathy [letter]. Lancet 1995; 345: 1644.
18. Natazuka T, Ogawa R, Kizaki T, et al. Immunosuppressive drugs and hypertrophic cardiomyopathy [letter]. Lancet 1995; 345: 1644.
19. Brand P, Brus F. Immunosuppressive drugs and hypertrophic cardiomyopathy [letter]. Lancet 1005; 345: 1644.
20. Baruch Y, Weitzman E, Markiewicz W, et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to neoral. Transplant Proc 1996; 28: 2250.
21. Dollinger M, Plevris J, Chauhan A, et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients. Lancet 1995; 346: 507.
22. Chang RK, Alzona M, Alejos J, et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol 1998; 81: 1277.
23. Atkison PR, Joubert GI, Guiraudon C, et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation 1997; 64: 773.
24. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61: 1188.
25. Scott JS, Boyle GJ, Daubeny PE, et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? Transplant Proc 1999; 31: 82.
26. Cenac A, Simonoff M, Moretto P, et al. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol 1992; 36: 57.